SNNA Sienna Biopharmaceuticals Inc.

  0%
Previous Close
Open
Price To Book 0.05
Market Cap 0
Shares 30,907,542
Volume 0
Short Ratio
Av. Daily Volume 2,775,784
Stock charts supplied by TradingView

NewsSee all news

  1. Sebacia Announces Leadership Update and Acquisition of Silver Photoparticle Technology Assets from Sienna Biopharmaceuticals

    DULUTH, Ga., Jan. 9, 2020 /PRNewswire/ -- Sebacia, Inc., a privately held commercial stage dermatology and aesthetics company, today provided a business update, first announcing an update to its leadership team. Mr.

  2. Sienna Biopharmaceuticals Announces Court Approval of Chapter 11 Bidding Procedures

    WESTLAKE VILLAGE, Calif., Nov. 14, 2019 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA) (the "Company"), a clinical-stage biopharmaceutical company, today announced that, on November 13, 2019,

  3. Sienna Biopharmaceuticals Announces Successful Appeal of Nasdaq Delisting Notice

    -- Sienna's common stock to remain conditionally listed during the Chapter 11 asset sale process WESTLAKE VILLAGE, Calif., Nov. 14, 2019 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA)

  4. Sienna Biopharmaceuticals Initiates Voluntary Chapter 11 Protection Proceeding

    WESTLAKE VILLAGE, Calif., Sept. 17, 2019 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA), a clinical-stage biopharmaceutical company, today announced that it has elected to file a voluntary petition

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 data met non-inferiority primary endpoint - February 8, 2019. Seeking partner for further advancement.
SNA-001
Reduction of light-pigmented hair
Phase 3 data released July 30, 2018 did not meet primary endpoint.
SNA-001
Acne
Phase 2b trial did not meet primary endpoint. Phase 3 trial to be initiated 2H 2019.
SNA-120
Pruritus associated with psoriasis
Phase 1/2 data released August 27, 2018.
SNA-125
Psoriasis
Phase 2 trial planned.
SNA-125
Atopic dermatitis

Latest News

  1. Sebacia Announces Leadership Update and Acquisition of Silver Photoparticle Technology Assets from Sienna Biopharmaceuticals

    DULUTH, Ga., Jan. 9, 2020 /PRNewswire/ -- Sebacia, Inc., a privately held commercial stage dermatology and aesthetics company, today provided a business update, first announcing an update to its leadership team. Mr.

  2. Sienna Biopharmaceuticals Announces Court Approval of Chapter 11 Bidding Procedures

    WESTLAKE VILLAGE, Calif., Nov. 14, 2019 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA) (the "Company"), a clinical-stage biopharmaceutical company, today announced that, on November 13, 2019,

  3. Sienna Biopharmaceuticals Announces Successful Appeal of Nasdaq Delisting Notice

    -- Sienna's common stock to remain conditionally listed during the Chapter 11 asset sale process WESTLAKE VILLAGE, Calif., Nov. 14, 2019 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA)

  4. Sienna Biopharmaceuticals Initiates Voluntary Chapter 11 Protection Proceeding

    WESTLAKE VILLAGE, Calif., Sept. 17, 2019 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA), a clinical-stage biopharmaceutical company, today announced that it has elected to file a voluntary petition